This Article Full Text Full Text (PDF) Supplementary Data, Bardella, et al. Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bardella, C. Articles by Di Renzo, M. F. Search for Related Content PubMed PubMed Citation Articles by Bardella, C. Articles by Di Renzo, M. F.

The Therapeutic Potential of Hepatocyte Growth Factor to Sensitize Ovarian Cancer Cells to Cisplatin and Paclitaxel In vivo

Authors' Affiliations: ¹ Laboratory of Cancer Genetics and ² Division of Molecular Oncology of the Institute for Cancer Research and Treatment, University of Torino School of Medicine, Candiolo (Turin), Italy

Requests for reprints: Maria Flavia Di Renzo, Laboratory of Cancer Genetics of the Institute for Cancer Research and Treatment, University of Turin Medical School, SP 142, KM 3.95, 10060, Candiolo (Turin), Italy. Phone: 39-11-993-3343; Fax: 39-11-993-3524; E-mail: mariaflavia.direnzo{at}ircc.it.

Purpose: Advanced ovarian cancers are initially responsive to combinatorial chemotherapy with platinum drugs and taxanes but, in most cases, develop drug resistance. We recently showed that, in vitro, hepatocyte growth factor (HGF) enhances death of human ovarian cancer cell lines treated with cisplatin (CDDP) and paclitaxel. The present study addresses whether in vivo HGF makes ovarian carcinoma cells more responsive to these chemotherapeutics.

Experimental Design: Using Lentiviral vectors carrying the HGF transgene, we transduced SK-OV-3 and NIH:OVCAR-3 ovarian carcinoma cell lines to obtain stable autocrine and paracrine HGF receptor activation. In vitro, we assayed growth, motility, invasiveness, and the response to CDDP and paclitaxel of the HGF-secreting bulk unselected cell populations. In vivo, we tested the cytotoxic effects of the drugs versus s.c. tumors formed by the wild-type and HGF-secreting cells in immunocompromised mice. Tumor-bearing mice were treated with CDDP (i.p.) and paclitaxel (i.v.), combined in different schedules and doses.

Results: In vitro, HGF-secreting cells did not show altered proliferation rates and survival but were strongly sensitized to the death triggered by CDDP and paclitaxel, alone or in combination. In vivo, we found a therapeutic window in which autocrine/paracrine HGF made tumors sensitive to low doses of the drugs, which were ineffective on their own.

Conclusions: These data provide the proof-of-concept that in vivo gene therapy with HGF might be competent in sensitizing ovarian cancer cells to conventional chemotherapy.

This article has been cited by other articles:

				Z. Tiran, A. Oren, C. Hermesh, G. Rotman, Z. Levine, H. Amitai, T. Handelsman, M. Beiman, A. Chen, D. Landesman-Milo, et al. A Novel Recombinant Soluble Splice Variant of Met Is a Potent Antagonist of the Hepatocyte Growth Factor/Scatter Factor-Met Pathway Clin. Cancer Res., July 15, 2008; 14(14): 4612 - 4621. [Abstract] [Full Text] [PDF]